Abstract
Cabergoline (CAB), a new long-acting ergoline derivative, was shown to be very effective in reducing PRL levels in normal volunteers and in hyperprolactinemic patients. We evaluated the hormonal changes after discontinuation of long-term therapy with CAB as well as the safety of drug exposure during pregnancy both for mothers and babies. We therefore studied 48 patients (47 females and one male) with pathological hyperprolactinaemia (mean±SE, 117.2±15.2; median 73.2 µg/l), treated for 1–82 months (mean±SE, 28.3±3; median 18). After long-term treatment, CAB was withdrawn in 11 patients and PRL levels were persistently normal for almost 15 days and significantly lower (p <0.05) than basal at 30, 45, 60, 90, 120 days. Three patients had normal PRL levels still at 45 days after treatment discontinuation. Nine patients became pregnant after 1–37 months (mean 12.4) of therapy. In two patients the pregnancy was interrupted spontaneously in one case and voluntarily in the other. In all but one patients, after delivery or three-month breast feeding, PRL levels trended towards reduction. In two cases (one with microadenoma and one with idiopathic hyperprolactinaemia) PRL remained in the normal levels for 1–3 years after delivery. In conclusion CAB is able to inhibit plasma PRL levels for long time (up to 120 days) after withdrawal in patients with pathological hyperprolactinaemia treated with long-term therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Pontiroli A.E., Viberti G.C., Mangili R., Cammelli L., Dubini A. Selective and extremely long inhibition of PRL release in man by 1-ethyl 3 (3′ Dimethylamino propyl) urea-diphosphate (FCE 21336). Br. J. Clin. Pharmacol. 23: 433, 1987.
Melis G.B., Gambacciani M., Paoletti A.M., Beneventi F., Mais V., Baroldi P., Fioretti P. Dose-related prolactin inhibitory effects of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal and hyperprolactinemic women. J. Clin. Endocrinol. Metab. 65: 541, 1987.
Ferrari C., Barbieri C., Caldara R., Mucci M., Codecasa F., Paracchi A., Romano C., Boghen M., Dubini A. Long lasting PRL-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J. Clin. Endocrinol. Metab. 63: 941, 1986.
Ciccarelli E., Giusti M., Miola C., Potenzoni F., Sghedoni D., Camanni F., Giordano G. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J. Clin. Endocrinol. Metab. 69: 725, 1989.
Ferrari C., Mattei A., Melis G.B., Paracchi A., Muratori M., Faglia G., Sghedoni D., Crosignani P.G. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. J. Clin. Endocrinol. Metab. 68: 1201, 1989.
Webster J., Piscitelli G., Polli A., Dalberto A., Farsetti L., Ferrari C., Fioretti P., Giordano G., L’Hermite M., Ciccarelli E., Crosignani P.G., De Cecco L., Fadini R., Faglia G., Flamigni C., Tamburrano G., Ismail I., Scanion M.F. (European multicentre CAB study group). The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. Clin. Endocrinol. 39: 323, 1993.
Ferrari C., Paracchi A., Mattei M., de Vincentiis S., D’Alberton A., Crosignani P.G. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol. (Copenh.) 126: 489, 1992.
Robert E., Musatti L., Piscitelli G., Ferrari C. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod. Toxicol. 10: 333, 1996.
Molitch M.E., Elton R.L., Blackwell R.E., Caldwell B., Chang R.J., Jaffe R., Joplin G., Robbins R.J., Tyson J., Thorner M.O. and the bromocriptine study group. Bromocriptine as primary therapy for PRL-secreting macroadenomas: results of a prospective multicenter study. J. Clin. Endocrinol. Metab. 60: 698, 1985.
Scotti G., Scialfa G., Pieralli S., Chiodini P.G., Spelta B., Dallabonzana D. Macroprolactinomas: CT evaluation of reduction of tumor size after medical treatment. Neuroradiology 23: 123, 1982.
Ciccarelli E., Miola C., Grottoli S., Avataneo T., Lancranjan J., Camanni F. Long term therapy of patients with macroprolactinomas using repeatable, injectable bromocriptine. J. Clin. Endocrinol. Metab. 76: 484, 1993.
Di Salle E., Ornati G., Briatico G. FCE 21336, a new ergoline derivative with long-acting lowering effect on prolactin secretion in rats. (Abstract). J. Endocrinol. Invest. 6(Suppl 1): 6, 1982.
Strolin Benedetti M., Dster P., Barone D., Efthymiopoulos C., Peretti G., Roncucci R. In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine. Eur. J. Pharmacol. 187: 399, 1990.
Di Salle E., Ornati G., Giudici D. A comparison of the in vivo and in vitro duration of prolactin lowering effect in rats of FCE 21336, pergolide and bromocriptine (Abstract). J. Endocrinol. Invest. 7(Suppl 1): 32, 1984.
Molitch M.E. Pregnancy and hyperprolactinemic women. New Engl. J. Med. 312: 1364, 1985.
Falsetti L., Zanagnolo V., Galbignani E. Cabergoline treatment in hyperprolactinemic women. J. Obstet. Gynaecol. 11: 68, 1991.
Webster J., Piscitelli G., Polli A., Ferrari C., Ismail I., Scanion M.F. for the cabergoline comparative study group. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. New Engl. J. Med. 331: 904, 1994.
Belforte L., Bruno M., Campagnoli C., Fessia L., Massara F., Molinatti G.M. Hormone patterns during bromocriptine-induced pregnancy in hyperprolactinemic patients. Eur. J. Obstet. Gynecol. Reprod. Biol. 10: 309, 1980.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ciccarelli, E., Grottoli, S., Razzore, P. et al. Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. J Endocrinol Invest 20, 547–551 (1997). https://doi.org/10.1007/BF03348017
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348017